HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class i HDACs on chromatin

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Romani, Bizhan ^a,b   Kamali Jamil, Razieh ^c   Hamidi Fard, Mojtaba ^d   Rahimi, Pooneh ^d   Momen, Seyed Bahman ^d   Aghasadeghi, Mohammad Reza ^d   Allahbakhshi, Elham ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HDAC1 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; PROTEASOME; VPR PROTEIN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CHROMATIN; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; METABOLISM; PHYSIOLOGY; PROMOTER REGION; PROTEIN DEGRADATION; PROVIRUS; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

CELL LINE; CHROMATIN; HEK293 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROVIRUSES; VIRUS ACTIVATION; VIRUS LATENCY; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84984619718     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31924     Document Type: Article

References (64)

1. Coiras, M., Lopez-Huertas, M. R., Perez-Olmeda, M. & Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Micro 7, 798-812 (2009)
2. McNamara, L. A., Ganesh, J. A. & Collins, K. L. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κ B activation. J Virol 88, 9337-9350 (2012)
3. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5, 512-517 (1999)
4. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997)
5. Poeschla, E. M. Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci 65, 1403-1424 (2008)
6. Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002)
7. Ruelas, D. S. & Greene, W. C. An integrated overview of HIV-1 latency. Cell 155, 519-529 (2013)
8. Friedman, J. et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2. J Virol 85, 9078-9089 (2011)
9. OBrien, S. K., Cao, H., Nathans, R., Ali, A. & Rana, T. M. P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes. J Biol Chem 285, 29713-29720 (2010)
10. Van Lint, C., Emiliani, S., Ott, M. & Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15, 1112-1120 (1996)
11. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 389, 349-352 (1997)
12. Bartova, E., Krejĉi, J., Harniĉarova, A., Galiova, G. & Kozubek, S. Histone modifications and nuclear rchitecture: a review. J Histochem Cytochem 56, 711-721 (2008)
13. Sheridan, P. L., Mayall, T. P., Verdin, E. & Jones, K. A. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11, 3327-3340 (1997)
14. Imai, K., Ochiai, K. & Okamoto, T. Reactivation of latent HIV-1 infection by the periodontopathic bacterium porphyromonas gingivalis involves histone modification. J Immun 182, 3688-3695 (2009)
15. Coull, J. J. et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase. J Virol 74, 6790-6799 (2000)
16. Lusic, M., Marcello, A., Cereseto, A. & Giacca, M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22, 6550-6561 (2003)
17. Edelstein, L. C., Micheva-Viteva, S., Phelan, B. D. & Dougherty, J. P. Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 25, 883-887 (2009)
18. Matalon, S., Rasmussen, T. A. & Dinarello, C. A. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 17, 466-472 (2011)
19. Laughlin, M. A. et al. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 196, 496-505 (1993)
20. Deeks, S. G. HIV: shock and kill. Nature 487, 439-440 (2012)
21. Lim, E. S. et al. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 11, 194-204 (2012)
22. Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type- 1 in mononuclear phagocytes. Virology 206, 935-944 (1995)
23. Romani, B. & Engelbrecht, S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90, 1795-1805 (2009)
24. Andersen, J. L. et al. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Path 12, e127 (2006)
25. Ahn, J. et al. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-RING E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem 285, 37333-37341 (2010)
26. Hrecka, K. et al. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Pro Nat Aca Sci USA 104, 11778-11783 (2007)
27. Tan, L., Ehrlich, E. & Yu, X.-F. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 81, 10822-10830 (2007)
28. Romani, B., Shaykh-Baygloo, N., Hamidi-Fard, M., Aghasadeghi, M. R. & Allahbakhshi, E. HIV-1 Vpr protein induces proteasomal degradation of chromatin-associated class I HDACs to overcome latent infection of macrophages. J Biol Chem 291, 2696-2711 (2016)
29. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012)
30. Barton, K. M. et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS ONE 9, e102684 (2014)
31. Bachand, F., Yao, X. J., Hrimech, M., Rougeau, N. & Cohen, E. A. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 Gag precursor. J Biol Chem 274, 9083-9091 (1999)
32. Paxton, W., Connor, R. I. & Landau, N. R. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 67, 7229-7237 (1993)
33. Iijima, K. et al. Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1. Retrovirology 10, 83 (2013)
34. Levy, D. N., Refaeli, Y., MacGregor, R. R. & Weiner, D. B. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Pro Nat Aca Sci USA 91, 10873-10877 (1994)
35. Romani, B., Shaykh-Baygloo, N., Aghasadeghi, M. R. & Allahbakhshi, E. HIV-1 Vpr protein enhances proteasomal degradation of MCM10 DNA replication factor through the Cul4-DDB1[VprBP] E3 ubiquitin ligase to induce G2/M cell cycle arrest. J Biol Chem 290, 17380-17389 (2015)
36. Hassig, C. A. et al. A role of histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Nat Acad Sci 95, 3519-3524 (1998)
37. Verdin, E., Paras, P. & Van Lint, C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12, 3249-3259 (1993)
38. He, G. & Margolis, D. M. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22, 2965-2973 (2002)
39. Huber, K. et al. Inhibitors of histone deacetylases: Correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 286, 22211-22218 (2011)
40. Siliciano, R. F. & Greene, W. C. HIV latency. Cold Spring Harbor Med 1, a007096 (2011)
41. Chiocca, S. et al. Histone deacetylase 1 inactivation by an adenovirus early gene product. Curr Biol 12, 594-598 (2002)
42. Sinclair, J. & Sissons, P. Latency and reactivation of human cytomegalovirus. J Gen Virol 87, 1763-1779 (2006)
43. Danaher, R. J. et al. Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript (LAT)-independent manner in neuronal cells. J Neurovirol 11, 306-317 (2005)
44. Lu, F. et al. Chromatin remodeling of the kaposis sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol 77, 11425-11435 (2003)
45. Ego, T., Ariumi, Y. & Shimotohno, K. The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. Oncogene 21, 7241-7246 (2002)
46. Herbein, G. & Wendling, D. Histone deacetylases in viral infections. Clin Epigenetics 1, 13-24 (2010)
47. Everett, R. D., Parsy, M. L. & Orr, A. Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J Virol 83, 4963-4977 (2009)
48. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25 (2009)
49. Romani, B., Engelbrecht, S. & Glashoff, R. H. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 91, 1-12 (2010)
50. Wang, X. et al. HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem 288, 15474-15480 (2013)
51. Vanitharani, R. et al. HIV-1 Vpr transactivates LTR-directed expression through sequences present within - 278 to - 176 and increases virus replication in vitro. Virology 289, 334-342 (2001)
52. Hogan, T. H., Nonnemacher, M. R., Krebs, F. C., Henderson, A. & Wigdahl, B. HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 57, 41-48 (2003)
53. Hrimech, M., Yao, X. J., Bachand, F., Rougeau, N. & Cohen, E. A. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 73, 4101-4109 (1999)
54. Philippon, V., Matsuda, Z. & Essex, M. Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx. J Hum Virol 2, 167-174 (1999)
55. Levy, D. N., Refaeli, Y. & Weiner, D. B. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 69, 1243-1252 (1995)
56. Miller, L. K. et al. Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology 10, 1-15 (2013)
57. Victoriano, A. F. B. et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Let 585, 1103-1111 (2011)
58. Marban, C. et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 26, 412-423 (2007)
59. Williams, S. A. et al. NF-κ B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. The EMBO Journal 25, 139-149 (2006)
60. Kiernan, R. et al. Post-activation turn-off of NF-κ B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278, 2758-2766 (2003)
61. Brandl, A. et al. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol 4, 284-293 (2012)
62. Kelly, Richard D. W. & Cowley Shaun, M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 41, 741-749 (2013)
63. Ropero, S. & Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1, 19-25 (2007)
64. Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4, e6093 (2009)